Chanda Sanjay 4
4 · AN2 Therapeutics, Inc. · Filed Jan 7, 2026
Insider Transaction Report
Form 4
Chanda Sanjay
Chief Development Officer
Transactions
- Sale
Common Stock
2026-01-05$1.00/sh−3,295$3,305→ 81,779 total - Sale
Common Stock
2026-01-06$1.01/sh−5,956$6,027→ 75,823 total
Footnotes (3)
- [F1]Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026.
- [F2]Includes (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 50,250 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.
- [F3]Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's Employee Stock Purchase Plan on September 30, 2025.